MTOR and colorectal carcinoma: The use of mTOR inhibitors in CRC treatment might be promising, and the logic for combining them with other chemotherapeutic medications such as irinotecan is reasonable, but it will need the identification of subgroups of individuals who are most likely to respond [177].